GlassScriptPhysician profile
Misti D Marsh
NPI 1467172387
$3,070.23
in general payments reported to CMS, 2019-2025
40 companies · $1,141 in 2025
The $1,141 reported for 2025 was more than what 87% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $268 · 2023: $803 · 2024: $857 · 2025: $1,141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,802.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,801.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $424.23 | 2023-2025 | |
| Lilly USA, LLC | $222.91 | 2023-2024 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $213.35 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Axsome Therapeutics, INC. | $206.04 | 2024-2025 | Auvelity |
| Sumitomo Pharma America, INC. | $179.32 | 2023-2025 | Gemtesa, Orgovyx, Myfembree |
| Astrazeneca Pharmaceuticals LP | $139.31 | 2025 | Airsupra, Fasenra, Breztri |
| Medtronic, INC. | $137.76 | 2022-2023 | Interstim |
| Takeda Pharmaceuticals U.S.A., INC. | $119.41 | 2023-2025 | Glassia, Trintellix |
| Glaxosmithkline, LLC. | $95.54 | 2023-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Exact Sciences Corporation | $91.95 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Corium, LLC | $84.52 | 2023-2025 | Azstarys |
| Novartis Pharmaceuticals Corporation | $84.37 | 2023-2024 | |
| 180 Medical, INC. | $84.02 | 2022-2023 | |
| Phathom Pharmaceuticals, INC. | $82.03 | 2024-2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $77.07 | 2024-2025 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $72.02 | 2022-2023 | Keytruda, Lynparza, Welireg |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $69.46 | 2023-2025 | Caplyta |
| Tolmar, INC. | $64.78 | 2023 | |
| Astellas Pharma US INC | $59.75 | 2022-2023 | Myrbetriq |
| Pfizer INC. | $53.33 | 2024-2025 | |
| Myovant Sciences INC. | $49.93 | 2022 | |
| C. R. Bard, INC. & Subsidiaries | $49.45 | 2023 | Bard Urinary Drainage Bag |
| Verona Pharma, INC. | $39.15 | 2025 | Ohtuvayre |
| Urovant Sciences INC | $36.24 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $34.32 | 2023-2025 | Rexulti |
| Inspire Medical Systems, INC. | $31.35 | 2025 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.41 | 2024-2025 | Jardiance |
| Janssen Biotech, INC. | $29.12 | 2022-2023 | Erleada |
| Accord Healthcare, INC. | $24.07 | 2023 | |
| Myriad Genetic Laboratories, INC. | $22.33 | 2022 | |
| Tolmar Pharmaceuticals, INC. | $20.00 | 2022 | |
| Endo Pharmaceuticals INC. | $19.59 | 2023 | Aveed, Xiaflex |
| Lundbeck LLC | $18.04 | 2025 | Rexulti |
| Alnylam Pharmaceuticals INC. | $17.65 | 2023 | Givlaari |
| Viatris Specialty LLC | $17.01 | 2025 | Yupelri |
| Coloplast Corp | $16.42 | 2023 | Altis |
| Amgen INC. | $16.40 | 2024 | Repatha, Otezla |
| Dexcom, INC. | $14.51 | 2025 | Dexcom G6 Transmitter |
| Mylan Specialty L.P. | $14.48 | 2024 | Yupelri |
| Organon LLC | $8.59 | 2023 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Misti Marsh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.